Literature DB >> 27535666

A modified MS-PCR approach to diagnose patients with Prader-Willi and Angelman syndrome.

Jéssica Fernandes Dos Santos1, Laís R Mota1, Pedro Henrique Silva Andrade Rocha1, Renata Lúcia L Ferreira de Lima2.   

Abstract

Prader-Willi (PWS) and Angelman (AS) syndromes are clinically distinct neurodevelopmental genetic diseases with multiple phenotypic manifestations. They are one of the most common genetic syndromes caused by non-Mendelian inheritance in the form of genomic imprinting, and can be attributable to the loss of gene expression due to imprinting within the chromosomal region 15q11-q13. Clinical diagnosis of PWS and AS is challenging, and the use of molecular and cytomolecular studies is recommended to help in determining the diagnosis of these conditions. The methylation analysis is a sensible approach; however there are several techniques for this purpose, such as the methylation-sensitive polymerase chain reaction (MS-PCR). This study aims to optimize the MS-PCR assay for the diagnosis of potential PWS and AS patients using DNA modified by sodium bisulfite. We used the MS-PCR technique of PCR described by Kosaki et al. (1997) adapted with betaine. All different concentrations of betaine used to amplify the methylated and unmethylated chromosomal region 15q11-q13 on the gene SNRPN showed amplification results, which increased proportionally to the concentration of betaine. The methylation analysis is a technically robust and reproducible screening method for PWS and AS. The MS-PCR assures a faster, cheaper and more efficient method for the primary diagnosis of the SNRPN gene in cases with PWS and AS, and may detect all of the three associated genetic abnormalities: deletion, uniparental disomy or imprinting errors.

Entities:  

Keywords:  Betaine; CpG islands; Enhancers; Genomic imprinting; Molecular diagnosis

Mesh:

Substances:

Year:  2016        PMID: 27535666     DOI: 10.1007/s11033-016-4055-2

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  35 in total

1.  The feasibility of PCR-based diagnosis of Prader-Willi and Angelman syndromes using restriction analysis after bisulfite modification of genomic DNA.

Authors:  M Velinov; H Gu; M Genovese; C Duncan; W T Brown; E Jenkins
Journal:  Mol Genet Metab       Date:  2000-01       Impact factor: 4.797

2.  Problems in detecting mosaic DNA methylation in Angelman syndrome.

Authors:  Bernhard Horsthemke; Christina Lich; Karin Buiting; Roland Achmann; Christa Aulehla-Scholz; Alessandra Baumer; Joachim Bürger; Bernd Dworniczak; Dieter Gläser; Elke Holinski-Feder; Bart Janssen; Stephanie Kleinle; Lothar Kochhan; Ernst Krasemann; Cornelia Kraus; Peter Kroisel; Hansjörg Plendl; Sabine Purmann; Gabriele Sander; Heyko Skladny; Eva Spitzer; Barbara Thamm-Mücke; Raymonda Varon-Mateeva; Andreas Weinhäusel; Helga Weirich
Journal:  Eur J Hum Genet       Date:  2003-12       Impact factor: 4.246

3.  A new approach to touch down method using betaine as co-solvent for increased specificity and intensity of GC rich gene amplification.

Authors:  Daliparthy D Pratyush; Shalbha Tiwari; Ashok Kumar; Surya K Singh
Journal:  Gene       Date:  2012-01-28       Impact factor: 3.688

4.  An efficient and economic enhancer mix for PCR.

Authors:  Markus Ralser; Robert Querfurth; Hans-Jörg Warnatz; Hans Lehrach; Marie-Laure Yaspo; Sylvia Krobitsch
Journal:  Biochem Biophys Res Commun       Date:  2006-07-05       Impact factor: 3.575

5.  The renaming of mental retardation: understanding the change to the term intellectual disability.

Authors:  Robert L Schalock; Ruth A Luckasson; Karrie A Shogren; Sharon Borthwick-Duffy; Val Bradley; Wil H E Buntinx; David L Coulter; Ellis M Craig; Sharon C Gomez; Yves Lachapelle; Alya Reeve; Martha E Snell; Scott Spreat; Marc J Tassé; James R Thompson; Miguel A Verdugo; Michael L Wehmeyer; Mark H Yeager
Journal:  Intellect Dev Disabil       Date:  2007-04

6.  Evaluation of methylation analysis for diagnostic testing in 258 referrals suspected of Prader-Willi or Angelman syndromes.

Authors:  T Buchholz; J Jackson; L Robson; A Smith
Journal:  Hum Genet       Date:  1998-11       Impact factor: 4.132

7.  [Molecular diagnosis of Prader-Willi and Angelman syndromes: methylation, cytogenetics and FISH analysis].

Authors:  L Santa María; B Curotto; F Cortés; C Rojas; M A Alliende
Journal:  Rev Med Chil       Date:  2001-04       Impact factor: 0.553

8.  A unified rapid PCR method for detection of normal and expanded trinucleotide alleles of CAG repeats in huntington chorea and CGG repeats in fragile X syndrome.

Authors:  Tihomir Todorov; Albena Todorova; Bilyana Georgieva; Vanyo Mitev
Journal:  Mol Biotechnol       Date:  2010-06       Impact factor: 2.695

9.  Molecular diagnosis of the Prader-Willi and Angelman syndromes by detection of parent-of-origin specific DNA methylation in 15q11-13.

Authors:  B Dittrich; W P Robinson; H Knoblauch; K Buiting; K Schmidt; G Gillessen-Kaesbach; B Horsthemke
Journal:  Hum Genet       Date:  1992-11       Impact factor: 4.132

Review 10.  [Therapeutical approach of obesity in Prader-Willi Syndrome].

Authors:  Daniel F de Carvalho; Cíntia Cercato; Madson Q Almeida; Marcio C Mancini; Alfredo Halpern
Journal:  Arq Bras Endocrinol Metabol       Date:  2007-08
View more
  2 in total

Review 1.  Recommendations for the diagnosis and management of childhood Prader-Willi syndrome in China.

Authors:  Dai Yang-Li; Luo Fei-Hong; Zhang Hui-Wen; Ma Ming-Sheng; Luo Xiao-Ping; Liu Li; Wang Yi; Zhou Qing; Jiang Yong-Hui; Zou Chao-Chun
Journal:  Orphanet J Rare Dis       Date:  2022-06-13       Impact factor: 4.303

2.  A rapid and accurate methylation-sensitive high-resolution melting analysis assay for the diagnosis of Prader Willi and Angelman patients.

Authors:  Igor Ribeiro Ferreira; Wilton Darleans Dos Santos Cunha; Leonardo Henrique Ferreira Gomes; Hiago Azevedo Cintra; Letícia Lopes Cabral Guimarães Fonseca; Elenice Ferreira Bastos; Juan Clinton Llerena; Zilton Farias Meira de Vasconcelos; Letícia da Cunha Guida
Journal:  Mol Genet Genomic Med       Date:  2019-04-29       Impact factor: 2.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.